Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice

Epilepsy Research

Volumn 51, Issue 1-2, 2002, Pages 5-11

  Sun, Mei Zhen ^a   Van Rijn, Clementina ^b   Liu, Yu ^a   Wang, Ming Zheng ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Carbamazepine; Epilepsy; Isobologram; MES test; Polytherapy; Valproate

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ELECTRIC SHOCK; LETHAL DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTROSHOCK; FEMALE; LETHAL DOSE 50; MALE; MICE; SEIZURES; VALPROIC ACID;

EID: 0036752273     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00053-0     Document Type: Article

References (21)

1. Berenbaum M.C. What is synergy? Pharmacological Reviews. 41:1989;93-141.
2. Bliss C.I. The determination of dosage-mortality curves from small numbers. Quart. J. Pharm. 11:1938;192.
3. Bourgeois B., Beaumanoir A., Blajen B. Monotherapy with Valproate in primary generlized epilepsies. Epilepsia. 8:1987;S8-S11.
4. Bourgeois B.F.D. Anti-convulsant potency and neurotoxicity of Valproate alone and in combination with Carbamazepine or phenobarbital. Clin. Neuropharmacol. 11:1988;348-359.
5. Bourgeois B.F.D. Pharmacologic intervention and treatment of childhood seizure disorders:relative efficacy and safety of antiepileptic drugs. Epilepsia. S2:1994;8-23.
6. Brodie M.J. Drug interaction in epilepsy. Epilepsia. S1:1992;13-22.
7. Cynthia L.H., James Z., Elaine C.A.R., et al. Combination Valproate-Carbamazepine therapy in partial epilepsies resistant to Carbamazepine monotherapy. J. Epilepsy. 6:1993;91-94.
8. Davis R., Peters D.H., McTavish D. Valproic Acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:1994;332-372.
9. Ferrendelli J.A. Rational polypharmacy. Epilepsia. S2:1995;115-118.
10. Fischbacher E. Effect of reduction of anti-convulsants on well-being. Br. Med. J. (Clin. Res. Ed.). 285:1982;423-424.
11. Lesser R.P., Pippenger C.E., Luders H., et al. High-dose monotherapy in treatment of intractable seizures. Neurology. 34:1984;701-711.
12. Macdonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia. S2:1995;2-12.
13. Nakane Y., Okuma T., Takashi R., et al. Multi-institutional study of the teratogenicity and fetal toxicity of antiepileptic drugs:a report of a collaborative study group in Japan. Epilepsia. 21:1980;663-680.
14. Pierre J. The Problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia. S9:1997;37-42.
15. Reynolds E.H., Shorvon S.D. Monotherapy or polytherapy for epilepsy? Epilepsia. 22:1981;1-10.
16. Roks G., Deckers C.L.P., Meinardi H., et al. Effects of polytherapy compared with monotherapy in anti-epileptic drugs:an animal study. J. Pharmacol. Exp.Ther. 288:1999;472-477.
17. Schmidt D., Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drug. 3:1995;94-208.
18. Swinyard E.A., Woodhead J.H., White H.S., et al. Levy R.H., Dreyfuss M.B., Mattson R.H., et al. Antiepileptic Drugs. Experimental Selection, Quantification, and Evaluation of Anti-convulsants. 1989;85-102 Raven Press, New York.
19. Tallarida R.J., Porreca F., Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 45:1989;947-961.
20. Tallarida R.J. Statistical analysis of combinations for synergism. Pain. 49:1992;93-97.
21. Van Rijn C.M., Willems E., Rodrigues de Miranda J.F., et al. A molecular model for the synergic interaction between GABA and general anaesthetics. Eur. J. Pharmacol. 371:1999;213-226.